Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis

Nov 30, 2012 - GlobalData - 41 pages - USD $3,495
Abstract Table of Contents Request Details Related
GlobalData has released its new PharmaPoint Drug Evaluation report, Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

Rituxan was co-developed and marketed in the US (under the brand name Rituxan) by Biogen Idec and Genentech (now a part of Roche). It is marketed outside of the US by Roche under the brand name MabThera. Rituxan was initially approved for the treatment of lymphoma and it was the first mAb to be approved for the treatment of cancer. In 2006, Rituxan was approved in the US and 5EU for the treatment of moderate to severe active RA in patients who do not adequately respond to one or more TNF inhibitors.

Scope of this Report:
  • Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Rituxan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Rituxan for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy, India and Australia
Reasons to Get this Report:
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Rituxan performance
  • Obtain sales forecast for Rituxan from 2011-2022 in the US, Japan, UK, France, Germany, Spain, Italy, India and Australia

Order This Report
FORMAT: PDF $3,495 USD
LICENSE: Single-User
DELIVERY: By Email

EASY ORDERING
Once you’ve found the right report, click ‘order now’ and complete the checkout process using any major credit card, check or wire/bank transfer.

Need multi-user or enterprise license pricing? Contact us for a custom quote!
MC, Visa, AMEX, Diners, Discovery, JCB

The Fast Market Research Advantage
Only the Best
All of our research is sourced from the most trusted and established global analysts and consultancies

Client Focused
From start-ups to multinationals, we focus on providing the right research to our diverse client base

Shop Securely
Our US-based customer service team and eCommerce systems adhere to highest data security standards

Industry-leading Customer Support
Individualized assistance from our expert staff is never more than an email or phone call away


About the Publisher
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team.